Imatinib in the Treatment of Chronic Myeloid Leukemia in Children and Adolescents is Effective and well-tolerated. Report of the Polish Pediatric Study Group for Treatment of Leukemias and Lymphomas

Abstract

Background. Chronic myeloid leukemia (CML) constitutes only 2-3% of all leukemias in pediatric patients. Philapelphia chromosome and BCR-ABL fusion are genetic hallmarks of CML, and their presence is crucial for targeted molecular therapy with tyrosine kinase inhibitors (TKIs), which replaced hematopoietic stem cell transplantation (HSCT) as a standard first-line therapy. The disease in pediatric population is rare, and despite molecular and clinical similarities to CML in adults, different approach is needed, due to the long lifetime expectancy and distinct developmental characteristics of affected children.Objectives. The objective of this study is to evaluate treatment with imatinib in Polish pediatric patients with CML. Material and methods.We analyzed the results of treatment with imatinib in 57 pediatric patients (June 2006 -January 2016) from 14 Polish pediatric hematology and oncology centers.Results. In the study group, 40 patients continued imatinib (median follow-up: 23.4 months), while in 17 the treatment was terminated (median follow-up: 15. 1 months) due to therapy failure. In the latter group, 13 patients underwent HSCT, while 4 switched to second-generation TKIs. The 5-year overall survival rate (OS) in the study group was 96%, and the 5-year event-free survival (EFS) was 81%. Conclusions.Our results confirm that the introduction of TKI therapy has revolutionized the treatment of CML in the pediatric population by replacing the previous method of treatment with HSCT and allowing a high percentage of OS and EFS.